Skip to main content

Dabrafenib Mesylate

Placeholder slot
 (duh-BRA-feh-nib MEH-zih-layt)

This page contains brief information about dabrafenib mesylate and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.

US Brand Name(s)
FDA Approved

FDA label information for this drug is available at DailyMed.

Use in Cancer

Dabrafenib mesylate is approved to be used alone or with trametinib to treat:

Dabrafenib mesylate is used only in patients whose cancer has a certain mutation in the BRAF gene.

Dabrafenib mesylate is also being studied in the treatment of other types of cancer.

More About Dabrafenib Mesylate

Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.

MedlinePlus Information on Dabrafenib Mesylate - A lay language summary of important information about this drug that may include the following:

  • warnings about this drug,
  • what this drug is used for and how it is used,
  • what you should tell your doctor before using this drug,
  • what you should know about this drug before using it,
  • other drugs that may interact with this drug, and
  • possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.

Research Results and Related Resources

Targeted Cancer Therapies

Targeted Treatment for Rare Digestive Tract Cancers May Extend Survival

Dabrafenib–Trametinib Combination Approved for Melanoma, Anaplastic Thyroid Cancer

Clinical Trials Accepting Patients

Find Clinical Trials for Dabrafenib Mesylate - Check for trials from NCI's list of cancer clinical trials now accepting patients.

  • Posted:
  • Updated: